PARTNERSHIP

Our proprietary technology platform enables the development of effective and differentiated products in multiple indications, for which neurogenic inflammation is underlying.

We initiate collaborations:

CURRENT STATUS

> Launch of TEDRA, a cosmeceutical product developed between 2019-2021 to hydrate and soothe sensitive areas.

This product was tested and approved by the BURN FOUNDATION who whished to offer patients a quality topical product for soothing and hydrating painful scars.

DISCOVER TEDRA

> We are working on the development of a first line drug for diabetic peripheral neuropathic pain (DPNP) with a focus on preclinical development in 2022.

> Several other R&D programs are in the pipeline, in chronic inflammatory and neurodegenerative diseases.

Fondation-des-brules-logo